Showing papers by "Joachim von Pawel published in 2018"
TL;DR: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel and continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.
176 citations
TL;DR: The post‐PD efficacy and safety data from OAK are consistent with a positive benefit‐risk profile of atezolizumab TBP in patients performing well clinically at the time of PD, and were not associated with increased safety risks.
80 citations
TL;DR: The patient‐reported outcomes data revealed that atezolizumab prolonged the time to the worsening of disease‐related symptoms, such as chest pain, and maintained patients’ health‐related quality of life, which further support the use of the investigational drug in the treatment of advanced NSCLC.
53 citations
TL;DR: The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.
Abstract: Lessons learned The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populationsFuture efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents Background Epidermal growth factor-like domain 7 (EGFL7) is an extracellular matrix-associated protein that is upregulated during angiogenesis and supports endothelial cell survival This phase II trial evaluated the efficacy of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for advanced or recurrent nonsquamous non-small cell lung cancer (NS-NSCLC) Methods Patients (n = 104) were randomized to either placebo or parsatuzumab (600 mg) in combination with bevacizumab (15 mg/kg) and carboplatin/paclitaxel, administered on day 1 of each 21-day cycle Carboplatin and paclitaxel were administered for up to six cycles Bevacizumab and parsatuzumab/placebo were administered for a maximum of 24 months Results The progression-free survival (PFS) hazard ratio (HR) was 17 (95% confidence interval [CI], 10-28; p = 047) The median PFS was 67 months for the parsatuzumab arm versus 81 months for the placebo arm The hazard ratio for overall survival (OS) was 11 (95% CI, 05-22; p = 847) The objective response rate (ORR) was 29% in the parsatuzumab arm and 56% in the placebo arm Overall safety and tolerability were consistent with the established toxicity profile of bevacizumab Conclusion There was no evidence of efficacy for the addition of parsatuzumab to the combination of bevacizumab and chemotherapy for first-line NS-NSCLC
13 citations
TL;DR: This ongoing, double-blind, randomized, global clinical trial evaluated the efficacy, safety, and immunogenicity of PF-06439535 vs. reference bevacizumab sourced from Tournaisia for the treatment of central giant cell granuloma.
Abstract: 109Background: This ongoing, double-blind, randomized, global clinical trial (NCT02364999) evaluated the efficacy, safety, and immunogenicity of PF-06439535 vs. reference bevacizumab sourced from t...
2 citations